We report here a very rare case of a nephrotic patient who developed acute myelogenous leukemia (AML, M2) 8 months after receiving cyclosporin A (CsA) therapy. A 30-year-old man with nephrotic syndrome had been taking diphenylhydantoin (DPH, 300 mg/day) for 6 years for treatment of convulsion and then received treatment of prednisolone and CsA (75 mg/day) for a nephrotic syndrome. Approximately 4 months after CsA therapy began, myeloblasts appeared in his peripheral blood at a ratio of 1%. Four months later, bone marrow aspiration and a biopsy confirmed a diagnosis of AML M2, showing hypercellular bone marrow with 60% leukemic cells. He received induction chemotherapy, which led to a complete remission.

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.41.722DOI Listing

Publication Analysis

Top Keywords

acute myelogenous
8
myelogenous leukemia
8
nephrotic patient
8
csa therapy
8
nephrotic syndrome
8
bone marrow
8
leukemia treatment
4
treatment cyclosporin
4
nephrotic
4
cyclosporin nephrotic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!